Company: BLCO
Filing Date: 2025-04-30
Form Type: 10-Q
Source: 0001860742-25-000008
Chunk: 45

Company: Bausch & Lomb Corp
Filing Date: 2025-04-30
Form: 10-Q
Item: Item 8
Chunk 45
---
 three months ended March 31, 2025 and 2024 were as follows:Vision CarePharmaceuticalsSurgicalTotalThree Months Ended March 31,(in millions)20252024202520242025202420252024RevenuesProduct Sales$654 $633 $266 $266 $213 $195 $1,133 $1,094 Other Revenues2 2 1 1 1 2 4 5 656 635 267 267 214 197 1,137 1,099 ExpensesCost of goods sold (excluding amortization and impairments of intangible assets)251 225 93 85 137 113 Cost of other revenues— — 1 1 — — Selling, general and administrative221 219 153 122 73 64 Research and development8 13 9 6 11 9 Segment Profit$176 $178 $11 $53 $(7)$11 180 242 Corporate(174)(153)Amortization of intangible assets(67)(74)Other expense, net(22)(9)Operating (loss) income(83)6 Interest income3 3 Interest expense(94)(99)Foreign exchange and other (6)— Loss before provision for income taxes$(180)$(90)Revenues by Segment and by Product CategoryRevenues by segment and product category were as follows:Vision CarePharmaceuticalsSurgicalTotalThree Months Ended March 31,(in millions)20252024202520242025202420252024Pharmaceuticals$1 $1 $221 $208 $— $— $222 $209 Devices235 229 — — 213 195 448 424 OTC409 395 — — — — 409 395 Branded and Other Generics9 8 45 58 — — 54 66 Other revenues2 2 1 1 1 2 4 5 $656 $635 $267 $267 $214 $197 $1,137 $1,099 The top ten products/franchises represented 55% and 54% of total revenues for the three months ended March 31, 2025 and 2024, respectively.